SK2142002A3 - Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras - Google Patents

Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras Download PDF

Info

Publication number
SK2142002A3
SK2142002A3 SK214-2002A SK2142002A SK2142002A3 SK 2142002 A3 SK2142002 A3 SK 2142002A3 SK 2142002 A SK2142002 A SK 2142002A SK 2142002 A3 SK2142002 A3 SK 2142002A3
Authority
SK
Slovakia
Prior art keywords
protein
ras
raf
angiogenesis
tissue
Prior art date
Application number
SK214-2002A
Other languages
English (en)
Slovak (sk)
Inventor
John Hood
Brian Eliceiri
David A Cheresh
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SK2142002A3 publication Critical patent/SK2142002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SK214-2002A 1999-08-13 2000-08-11 Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras SK2142002A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14892499P 1999-08-13 1999-08-13
US21595100P 2000-07-05 2000-07-05
PCT/US2000/021842 WO2001012210A1 (en) 1999-08-13 2000-08-11 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras

Publications (1)

Publication Number Publication Date
SK2142002A3 true SK2142002A3 (en) 2002-07-02

Family

ID=26846311

Family Applications (1)

Application Number Title Priority Date Filing Date
SK214-2002A SK2142002A3 (en) 1999-08-13 2000-08-11 Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras

Country Status (17)

Country Link
US (1) US20060040853A1 (pt)
EP (1) EP1210099A4 (pt)
JP (1) JP2003507337A (pt)
KR (2) KR100805098B1 (pt)
CN (1) CN1208087C (pt)
AU (1) AU781877B2 (pt)
BR (1) BR0013228A (pt)
CA (1) CA2380966A1 (pt)
CZ (1) CZ2002449A3 (pt)
HK (1) HK1050856A1 (pt)
HU (1) HUP0300923A3 (pt)
MX (1) MXPA02001553A (pt)
NO (1) NO20020718L (pt)
PL (1) PL364928A1 (pt)
RU (1) RU2257911C2 (pt)
SK (1) SK2142002A3 (pt)
WO (1) WO2001012210A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026246A2 (en) * 2000-09-29 2002-04-04 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Pharmaceutical compositions comprising polynucleotides encoding a raf protein
US8486941B2 (en) * 2007-03-12 2013-07-16 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2009091810A1 (en) * 2008-01-14 2009-07-23 Genentech, Inc. Methods for inhibiting angiogenesis using egfl8 antagonists
EP2329854A3 (de) * 2009-12-04 2014-02-19 Biotronik VI Patent AG Implantatbeschichtung mit Nukleinsäuren
CN102766601B (zh) * 2011-11-17 2015-12-16 中山大学肿瘤防治中心 含有可诱导型癌基因的细胞系及其建立方法、应用
JP6397937B2 (ja) 2014-06-03 2018-09-26 ヘレラ アルトゥーロ ソリス 角膜血管新生および角膜拡張性疾患の動物モデル、製造方法、およびその使用方法
RU2728870C2 (ru) * 2017-10-12 2020-07-31 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Полипептиды для лечения онкологических заболеваний
WO2021211784A2 (en) * 2020-04-15 2021-10-21 Cohbar, Inc. Method of treating coronavirus infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156841A (en) * 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
US5618670A (en) * 1988-08-26 1997-04-08 The United States Of America As Represented By The Department Of Health & Human Services Detection method for c-raf-1 genes
US5656612A (en) 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5597719A (en) 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US6300081B1 (en) * 1996-11-15 2001-10-09 Cornell Research Foundation, Inc. Activated ras interaction assay
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods

Also Published As

Publication number Publication date
KR100759241B1 (ko) 2007-09-18
US20060040853A1 (en) 2006-02-23
EP1210099A1 (en) 2002-06-05
AU6763300A (en) 2001-03-13
HUP0300923A3 (en) 2005-12-28
NO20020718L (no) 2002-04-10
CN1208087C (zh) 2005-06-29
RU2257911C2 (ru) 2005-08-10
KR20070067210A (ko) 2007-06-27
WO2001012210A1 (en) 2001-02-22
NO20020718D0 (no) 2002-02-12
CN1378457A (zh) 2002-11-06
HK1050856A1 (en) 2003-07-11
CZ2002449A3 (cs) 2002-08-14
PL364928A1 (en) 2004-12-27
MXPA02001553A (es) 2003-05-23
BR0013228A (pt) 2003-06-17
CA2380966A1 (en) 2001-02-22
WO2001012210A9 (en) 2002-09-12
KR100805098B1 (ko) 2008-02-20
AU781877B2 (en) 2005-06-16
KR20020032553A (ko) 2002-05-03
EP1210099A4 (en) 2006-01-18
HUP0300923A2 (hu) 2003-07-28
JP2003507337A (ja) 2003-02-25

Similar Documents

Publication Publication Date Title
US7585841B2 (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src
EP1905457B1 (en) Pharmaceutical compositions comprising Src and/or Yes and their use
US20060040853A1 (en) Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras
US6685938B1 (en) Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US6271205B1 (en) Cancer treatment by expression of differentiation factor receptor
ZA200201761B (en) Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras.
MXPA02006207A (en) Angiogenesis and vascular permeability modulators and inhibitors

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure